160 related articles for article (PubMed ID: 28209754)
1. Myelodysplastic syndrome with excess blasts-2 associated with erythroid predominance.
Pourabdollah M; Chang H
Blood; 2017 Feb; 129(7):918. PubMed ID: 28209754
[No Abstract] [Full Text] [Related]
2. Erythroid proliferations in myeloid neoplasms.
Wang SA; Hasserjian RP
Hum Pathol; 2012 Feb; 43(2):153-64. PubMed ID: 22154053
[TBL] [Abstract][Full Text] [Related]
3. Acute myeloid leukaemia and myelodysplastic syndromes with 50% or greater erythroblasts: a diagnostic conundrum.
Wong E; Juneja S
Pathology; 2015 Jun; 47(4):289-93. PubMed ID: 25938365
[TBL] [Abstract][Full Text] [Related]
4. Pure erythroid leukemia: a reassessment of the entity using the 2008 World Health Organization classification.
Liu W; Hasserjian RP; Hu Y; Zhang L; Miranda RN; Medeiros LJ; Wang SA
Mod Pathol; 2011 Mar; 24(3):375-83. PubMed ID: 21102413
[TBL] [Abstract][Full Text] [Related]
5. Erythroleukemia shares biological features and outcome with myelodysplastic syndromes with excess blasts: a rationale for its inclusion into future classifications of myelodysplastic syndromes.
Calvo X; Arenillas L; Luño E; Senent L; Arnan M; Ramos F; Ardanaz MT; Pedro C; Tormo M; Montoro J; Díez-Campelo M; Arrizabalaga B; Xicoy B; Bonanad S; Jerez A; Nomdedeu B; Ferrer A; Sanz GF; Florensa L
Mod Pathol; 2016 Dec; 29(12):1541-1551. PubMed ID: 27562492
[TBL] [Abstract][Full Text] [Related]
6. The effects of azacitidine on the response and prognosis of myelodysplastic syndrome and acute myeloid leukemia involving a bone marrow erythroblast frequency of >50.
Uchida T; Hagihara M; Hua J; Inoue M
Leuk Res; 2017 Feb; 53():35-38. PubMed ID: 28013105
[TBL] [Abstract][Full Text] [Related]
7. Considering Bone Marrow Blasts From Nonerythroid Cellularity Improves the Prognostic Evaluation of Myelodysplastic Syndromes.
Arenillas L; Calvo X; Luño E; Senent L; Alonso E; Ramos F; Ardanaz MT; Pedro C; Tormo M; Marco V; Montoro J; Díez-Campelo M; Brunet S; Arrizabalaga B; Xicoy B; Andreu R; Bonanad S; Jerez A; Nomdedeu B; Ferrer A; Sanz GF; Florensa L
J Clin Oncol; 2016 Sep; 34(27):3284-92. PubMed ID: 27382099
[TBL] [Abstract][Full Text] [Related]
8. Identification and quantitation of blasts in myeloid malignancies with marrow fibrosis or marrow hypoplasia and CD34 negativity.
Nedumannil R; Sim S; Westerman D; Juneja S
Pathology; 2021 Oct; 53(6):795-798. PubMed ID: 33612271
[No Abstract] [Full Text] [Related]
9. Marked erythropoietin-induced dysplastic erythropoiesis in a patient with myelodysplastic syndrome.
Narukawa K; Masuda A; Takahashi T
Int J Hematol; 2021 Jun; 113(6):775-776. PubMed ID: 33864622
[No Abstract] [Full Text] [Related]
10. Reproducibility of the World Health Organization 2008 criteria for myelodysplastic syndromes.
Senent L; Arenillas L; Luño E; Ruiz JC; Sanz G; Florensa L
Haematologica; 2013 Apr; 98(4):568-75. PubMed ID: 23065505
[TBL] [Abstract][Full Text] [Related]
11. Does a diagnosis of myelogenous leukemia require 20% marrow myeloblasts, and does <5% marrow myeloblasts represent a remission? The history and ambiguity of arbitrary diagnostic boundaries in the understanding of myelodysplasia.
Lichtman MA
Oncologist; 2013; 18(9):973-80. PubMed ID: 23982763
[TBL] [Abstract][Full Text] [Related]
12. The myelodysplastic syndromes. Part I. What are they? Part II. Classification.
Galton DA
Scand J Haematol Suppl; 1986; 45():11-20. PubMed ID: 3515515
[No Abstract] [Full Text] [Related]
13. Histopathology in the diagnosis of high-risk myelodysplastic syndromes.
Kayano H
J Clin Exp Hematop; 2018; 58(2):51-60. PubMed ID: 29998976
[TBL] [Abstract][Full Text] [Related]
14. Acute erythroid neoplastic proliferations. A biological study based on 62 patients.
Domingo-Claros A; Larriba I; Rozman M; Irriguible D; Vallespí T; Aventin A; Ayats R; Millá F; Solé F; Florensa L; Gallart M; Tuset E; Lopez C; Woessner S
Haematologica; 2002 Feb; 87(2):148-53. PubMed ID: 11836165
[TBL] [Abstract][Full Text] [Related]
15. Pure erythroid leukemia.
Wang W; Wang SA; Medeiros LJ; Khoury JD
Am J Hematol; 2017 Mar; 92(3):292-296. PubMed ID: 28006859
[TBL] [Abstract][Full Text] [Related]
16. [How to differentiate myelogenous leukemia FAB-type 6 (erythroleukemia) from the myelodysplastic syndrome?].
Stavem P; Evensen SA; Brinch L; Strømsheim JP
Tidsskr Nor Laegeforen; 1992 Aug; 112(19):2557-8. PubMed ID: 1412272
[No Abstract] [Full Text] [Related]
17. Epitaph for erythroleukemia.
Zini G; d'Onofrio G
Haematologica; 2004 Aug; 89(8):ELT11. PubMed ID: 15339700
[No Abstract] [Full Text] [Related]
18. Acute erythroid leukemia with <20% bone marrow blasts is clinically and biologically similar to myelodysplastic syndrome with excess blasts.
Wang SA; Patel KP; Pozdnyakova O; Peng J; Zuo Z; Dal Cin P; Steensma DP; Hasserjian RP
Mod Pathol; 2016 Oct; 29(10):1221-31. PubMed ID: 27443511
[TBL] [Abstract][Full Text] [Related]
19. Myelodysplastic syndrome with clonal cytogenetic abnormalities followed by fatal erythroid leukemia after 14 years of exposure to hydroxyurea for sickle cell anemia.
Aumont C; Driss F; Lazure T; Picard V; Creidy R; De Botton S; Saada V; Lambotte O; Bilhou-Nabera C; Tertian G; Michot JM
Am J Hematol; 2015 Jul; 90(7):E131-2. PubMed ID: 25801602
[No Abstract] [Full Text] [Related]
20. "Hof" in pronormoblasts: pure erythroid leukemia mimicking plasma cell myeloma.
Thakral B; Wang SA
Blood; 2017 Sep; 130(13):1600. PubMed ID: 28963106
[No Abstract] [Full Text] [Related]
[Next] [New Search]
